In Silico Screening of Natural Compounds to Identify Lead as Interleukin 17A Receptor Blockers as Antihypertensive AgentsIn Silico Screening of Natural Compounds to Identify Lead as Interleukin 17A Receptor Blockers as Antihypertensive Agents

Abstract

Objectives: Nature gives disease and nature gives the medicine. Natural products have exhibited paramount sources of novel drugs. Due to this, natural products have gained a dominant role in drug design and discovery. Interleukin 17 (IL-17) is a potent pro-inflammatory cytokine produced by activated memory T cells. Recent studies have created a vast amount of interest in the IL-17A as it is a key novel marker for the new potential therapeutic target for antihypertensive treatment. Materials and Methods: The X-ray crystallographic proteins of novel antihypertensive target interleukin 17A receptor blocker PDB ID 5hi5 were selected as receptors. The research has been carried out using computer-aided drug design to identify natural compounds using virtual screening to establish as a novel lead compound for a novel target of Antihypertensive by Inhibition interleukin 17A receptor blocker. Results: Out of one hundred fifty-one natural compounds, our research finding has put natural compound Gama (γ) –Oryzanol is a lead compound for developing novel interleukin 17A receptor blocker as antihypertensive agents. Conclusion: Therefore, the findings of this study may help researchers to identify new molecules or design of new molecules which can specifically be used as novel target interleukin 17A receptor blocker as antihypertensive agents after lead optimization.